Vanda Pharmaceuticals Inc.

Form 3

April 12, 2006

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

(Last)

Statement

04/12/2006

(Month/Day/Year)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]

 PROSPECT

MANAGEMENT CO II LLC (First)

(Middle)

5. If Amendment, Date Original

Filed(Month/Day/Year)

435 TASSO STREET, SUITE

200

(Street)

(State)

(Check all applicable)

(give title below) (specify below)

Person(s) to Issuer

4. Relationship of Reporting

Director __X__ 10% Owner Officer Other

6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting

Person

X Form filed by More than One

Reporting Person

PALO ALTO, Â CAÂ 94301

(City)

(Instr. 4)

1. Title of Security

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership Form: (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. 5. Conversion or Exercise

6. Nature of Indirect Ownership Beneficial Ownership Form of (Instr. 5)

(Instr. 4)

Expiration Title

Price of Derivative Security

Derivative Security:

Date

Exercisable Date

Amount or Number of

Direct (D)

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Series B Preferred Stock	(1)	(2)	Common Stock	2,366,655 (6)	\$ <u>(3)</u>	I	See Footnote (4)
Series B Preferred Stock	(1)	(2)	Common Stock	36,040 (6)	\$ (3)	I	See Footnote (5)

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
PROSPECT MANAGEMENT CO II LLC 435 TASSO STREET SUITE 200 PALO ALTO, CA 94301	Â	ÂX	Â	Â	
PROSPECT VENTURE PARTNERS II LP 435 TASSO STREET SUITE 200 PALO ALTO, CA 94301	Â	ÂX	Â	Â	
PROSPECT ASSOCIATES II L P 435 TASSO STREET SUITE 200 PALO ALTO, CA 94301	Â	ÂX	Â	Â	
SCHNELL DAVID 435 TASSO STREET SUITE 200 PALO ALTO, CA 94301	Â	ÂX	Â	Â	
BARKAS ALEXANDER E 435 TASSO STREET SUITE 200 PALO ALTO, CA 94301	Â	ÂX	Â	Â	
HIRSCH RUSSELL C 435 TASSO STREET SUITE 200 PALO ALTO, CA 94301	Â	ÂX	Â	Â	
Signatures					
/s/ James B. Tananbaum, M.D., Authorized Signatory		04/12/2	2006		
**Signature of Reporting Person		Date			

Explanation of Responses:

Reporting Owners 2

^{*} If the form is filed by more than one reporting person, see Instruction 5(b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 3

- (1) Immediately.
- (2) Not applicable.
- (3) Reflects the automatic conversion of each share of Series B Preferred Stock into one share of Common Stock to occur upon the close of business of the day immediately preceding the closing of the issuer's initial public offering.
 - The reportable securities are owned directly by Prospect Venture Partners II, L.P. Prospect Management Co. II, L.L.C. is the general partner of Prospect Venture Partners II, L.P. Prospect Management Co. II, L.L.C. disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Prospect Management Co. II, L.L.C. is the beneficial owner of such securities for
- (4) purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein. David Schnell, M.D., Alex Barkas, Ph.D., and Russell Hirsch, M.D. are managing members of Prospect Management Co. II, L.L.C. Each of Dr. Schnell, Dr. Barkas, and Dr. Hirsch disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein.
 - The reportable securities are owned directly by Prospect Associates II, L.P. Prospect Management Co. II, L.L.C. is the general partner of Prospect Associates II, L.P. Prospect Management Co. II, L.L.C. disclaims beneficial ownership of these securities and this report shall not be deemed an admission that Prospect Management Co. II, L.L.C. is the beneficial owner of such securities for purposes of Section 16
- (5) or for any other purpose, except to the extent of its pecuniary interest therein. David Schnell, M.D., Alex Barkas, Ph.D., and Russell Hirsch, M.D. are managing members of Prospect Management Co. II, L.L.C. Each of Dr. Schnell, Dr. Barkas, and Dr. Hirsch disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein.
- (6) Reflects a 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.